Enanta Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Enanta Pharmaceuticals

Enanta Pharmaceuticals is a research and development-focused biotechnology companythat uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The company is discovering and developing inhibitors designed for use against the hepatitis C virus, or HCV. These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes - protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase - as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin.In March 2013, Enanta Pharmaceuticals went public with a valuation of $235 million.

Enanta Pharmaceuticals Headquarters Location

500 Arsenal Street

Watertown, Massachusetts, 02472,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Enanta Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Enanta Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Enanta Pharmaceuticals Patents

Enanta Pharmaceuticals has filed 134 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • G protein coupled receptors
  • Prodrugs
patents chart

Application Date

Grant Date


Related Topics




Benzodiazepines, Lactams, Prodrugs, Monoclonal antibodies, Fluoroarenes


Application Date


Grant Date



Related Topics

Benzodiazepines, Lactams, Prodrugs, Monoclonal antibodies, Fluoroarenes



Latest Enanta Pharmaceuticals News

As Covid program advances, Enanta's new CMO says it's not 'limited to antivirals'; With all eyes on Gilead-partnered cancer drugs, Arcus brings medical chief on board

Aug 12, 2022

Associate Editor Ex­pect some pipeline ad­just­ments at Enan­ta Phar­ma­ceu­ti­cals in the com­ing years, be­cause new CMO Scott Rot­ting­haus thinks the an­tivi­ral biotech can ex­pand its hori­zons while al­so fig­ur­ing out a way to ad­dress the years­long Covid pan­dem­ic with an ex­pect­ed Phase II launch lat­er this year. “I would like to take a look at what we have as pos­si­bil­i­ties com­ing out of the lab. We have such a strong dis­cov­ery pro­gram,” Rot­ting­haus told End­points News. “I don’t think we need to be lim­it­ed to an­tivi­rals here at Enan­ta; we can take a broad­er look at some oth­er ther­a­peu­tic ar­eas.” Scott Rot­ting­haus For now, though, the for­mer hema­tol­ogy and nephrol­o­gy clin­i­cal de­vel­op­ment leader at Alex­ion, which last year was swooped up by As­traZeneca, is re­turn­ing to his roots in the in­fec­tious dis­ease field. In un­der­grad at Kansas State, poly­omavirus struc­tur­al pro­teins con­sumed Rot­ting­haus’ at­ten­tion. Then it was vac­cine work on measles and in­fluen­za dur­ing med­ical school and res­i­den­cy at Mayo Clin­ic. A stint work­ing on HSV came next, as an in­fec­tious dis­ease fel­low at the Uni­ver­si­ty of Al­aba­ma at Birm­ing­ham in the mid-aughts. An­timi­cro­bials and vac­cines took cen­ter stage dur­ing an eight-year post at Pfiz­er, in­clud­ing a clin­i­cal lead role on bac­te­r­i­al in­fec­tion med Ty­gacil. “Big Phar­ma in the past decade has lost some in­ter­est in an­ti-in­fec­tives, which is what caused me to kind of move away as op­por­tu­ni­ties knocked. When I heard about the op­por­tu­ni­ty at Enan­ta, it was ac­tu­al­ly a fair­ly easy choice for me,” the CMO said. In his telling, Rot­ting­haus is “very ex­cit­ed” or “re­al­ly ex­cit­ed” about the work ahead, mak­ing it clear four times in the first minute of an in­ter­view on day three in the new C-suite post. Covid-19 and res­pi­ra­to­ry syn­cy­tial virus are “right at the top of the list,” he said. Fol­low­ing Phase I da­ta on its once-dai­ly oral drug late last month, Enan­ta will meet with the FDA “in the very near fu­ture” to agree on a Phase II pro­gram for EDP-235, a 3CL pro­tease in­hibitor. That tri­al is slat­ed to be glob­al in scope to “move it for­ward as quick­ly as pos­si­ble,” the new CMO said. Enan­ta is al­so in the midst of su­ing Rot­ting­haus’ for­mer em­ploy­er, Pfiz­er, over the Big Phar­ma’s Covid drug, Paxlovid. Be­yond Covid, Rot­ting­haus will dig in­to a Phase IIb test­ing EDP-938 in adults at high risk for get­ting in­fect­ed with RSV. In May, the drug flunked a mid-stage test in oth­er­wise healthy adults with com­mu­ni­ty-ac­quired RSV. — Kyle LaHu­cik Dim­it­ry Nuyten → Things look a lit­tle hazier for Ar­cus Bio­sciences and Gilead’s CD73 can­di­date quem­li­clu­s­tat af­ter an­a­lysts voice their disp­point­ment with the lat­est up­date on a drug that “ ex­ceed­ed ex­pec­ta­tions ” at AACR in ear­ly 2021. Dim­it­ry Nuyten has now tak­en com­mand of Ar­cus’ clin­i­cal de­vel­op­ment as CMO and pre­sides over a pipeline that, along­side quem­li­clu­s­tat, in­cludes a clutch of can­cer drugs like dom­vanal­imab and etru­madenant at the heart of the $725 mil­lion deal with Gilead. The ex-med­ical chief at Nek­tar and Aduro Biotech, Nuyten has al­so been VP of glob­al prod­uct de­vel­op­ment for on­col­o­gy at Pfiz­er and a group med­ical di­rec­tor for Bris­tol My­ers Squibb. Math­ai Mam­men → The big names in J&J’s lead­er­ship struc­ture are grad­u­al­ly peel­ing away as head of R&D Math­ai Mam­men packs his bags to “pur­sue oth­er op­por­tu­ni­ties out­side of the Com­pa­ny,” ac­cord­ing to a state­ment that pro­vid­ed few de­tails be­yond his in­ter­im suc­ces­sor, chief in­no­va­tion of­fi­cer William Hait. Mam­men’s sud­den de­par­ture late Mon­day fol­lows that of ex-CSO Paul Stof­fels, who’s now reshuf­fling the deck at Gala­pa­gos as CEO , and it comes near­ly a year af­ter J&J first an­nounced that Joaquin Du­a­to would re­place Alex Gorsky as CEO. Win­selow Tuck­er → Eli Lil­ly’s Stephen Fry will re­tire at the end of the year as Loxo com­mer­cial chief Er­ic Dozi­er is set to re­place him as SVP, hu­man re­sources and di­ver­si­ty. Fry start­ed as a sys­tems an­a­lyst at the In­di­anapo­lis phar­ma in 1987 and has held his cur­rent role since 2011, while Dozi­er is al­so a long­time Lil­ly vet who’s held such roles as gen­er­al man­ag­er, Puer­to Ri­co and chief mar­ket­ing of­fi­cer for Japan. At the end of this month, Win­selow Tuck­er will leave Bris­tol My­ers and suc­ceed Dozi­er as Loxo’s chief com­mer­cial of­fi­cer. Tuck­er joined BMS from No­var­tis in 2019 as SVP and gen­er­al man­ag­er, US hema­tol­ogy and was el­e­vat­ed to SVP, in­ter­con­ti­nen­tal in Jan­u­ary. Sim­ba Gill → Sim­ba Gill will on­ly be CEO of Evelo Bio­sciences a lit­tle while longer, be­com­ing chair­man of Evelo’s board and head­ing back to Flag­ship Pi­o­neer­ing “to help launch, grow, and guide bio­plat­form com­pa­nies” as an ex­ec­u­tive part­ner. Both ap­point­ments will take ef­fect when a suc­ces­sor is named. As found­ing chief ex­ec­u­tive, Gill shep­herd­ed Evelo to an IPO in 2018 and in­to Phase II tri­als with its lead pro­gram in pso­ri­a­sis and atopic der­mati­tis. With the bear mar­ket hit­ting the sec­tor hard, Evelo cush­ioned the blow with a $79.2 mil­lion di­rect of­fer­ing in late May. Howard Davis → Bris­tol My­ers part­ner PsiOxus Ther­a­peu­tics, an Ox­ford, UK-based can­cer biotech once backed by Neil Wood­ford, has lined up Howard Davis as CEO. Davis jumps to the top spot here af­ter help­ing launch Third Har­mon­ic Bio as COO; the No­var­tis and Bio­gen alum has al­so been a prin­ci­pal at Flag­ship. Priya Mande, the in­ter­im chief for the last year, will be­come PsiOxus’ COO and UK pres­i­dent. Chris Franken­field → Xilio Ther­a­peu­tics propped open a win­dow in­to some ear­ly da­ta with XTX101 for sol­id tu­mors, and in the same re­lease, the biotech shared the pro­mo­tions of Uli Bialucha to CSO and Chris Franken­field to chief le­gal and ad­min­is­tra­tive of­fi­cer. Both ex­ecs ar­rived last year, with Bialucha orig­i­nal­ly join­ing Xilio from Im­mu­ni­tas Ther­a­peu­tics as SVP of re­search and Franken­field com­ing from Blue­print Med­i­cines to take on the role of gen­er­al coun­sel. Tim­o­thy Hunt → Tim­o­thy Hunt will take over as CEO of The Al­liance for Re­gen­er­a­tive Med­i­cine on Sept. 6, re­plac­ing Janet Lynch Lam­bert. Once part of ARM’s Gene Edit­ing Task Force, Hunt had just tak­en on the role of chief cul­ture and cor­po­rate af­fairs of­fi­cer at Xilio in Oc­to­ber 2021. He was al­so chief cor­po­rate af­fairs of­fi­cer at Ed­i­tas Med­i­cine from 2016-20 and a pub­lic af­fairs ex­ec with Bio­gen. Mike No­haile → Con­cur­rent with its $35 mil­lion Se­ries C haul, San Fran­cis­co’s Prel­lis Bi­o­log­ics has wel­comed Mike No­haile as CEO. No­haile leaves his CSO post at Flag­ship’s Gen­er­ate Bio­med­i­cines and his Big Phar­ma back­ground con­sists of mul­ti­ple roles over a 14-year pe­ri­od at No­var­tis (in­clud­ing four years as glob­al head of mol­e­c­u­lar di­ag­nos­tics) and Am­gen (round­ing out his tenure as SVP of strat­e­gy, com­mer­cial­iza­tion, and in­no­va­tion). Prel­lis teamed up with Bris­tol My­ers and Sanofi in sep­a­rate an­ti­body deals ear­li­er this year. → Ground­ed by the FDA with a clin­i­cal hold on its CAR-T drug BEAM-201 for re­lapsed/re­frac­to­ry T-cell acute lym­phoblas­tic leukemia and lym­phoma, Beam Ther­a­peu­tics has in­stalled John Lo as chief com­mer­cial of­fi­cer. Big Phar­ma con­nec­tions abound with Lo, who led the hema­tol­ogy fran­chise dur­ing his eight years at No­var­tis; worked on such drugs as Tagris­so and Imfinzi at As­traZeneca and was the phar­ma gi­ant’s head of glob­al mar­ket­ing and mar­ket ac­cess; and be­came SVP of world­wide hema­tol­ogy for Bris­tol My­ers in 2019 af­ter the Cel­gene buy­out. Ja­son Dami­ano → The Ap­pi­an Way : Los An­ge­les-based Ap­pia Bio — de­vel­op­ing off-the-shelf CAR ther­a­pies with in­vari­ant nat­ur­al killer T cells (iNKT) and team­ing up with Kite in a deal worth up to $875 mil­lion — has rolled out the wel­come mat for Ja­son Dami­ano as CSO. Dami­ano wraps up a three-year run at Uni­ty Biotech­nol­o­gy as VP of bi­ol­o­gy, and from 2016-18 he was di­rec­tor of ther­a­peu­tic an­ti­body dis­cov­ery and trans­la­tion­al med­i­cine at Achao­gen. Ex-Kite and Lyell CSO Mar­go Roberts has sewn up a spot on the board of di­rec­tors at Ap­pia Bio, a com­pa­ny chaired by No­bel lau­re­ate David Bal­ti­more and led by for­mer Tenaya pres­i­dent JJ Kang. Dou­glas Warn­er → Look­ing to re­group with its tomivosert­ib/Keytru­da com­bo in NSCLC while swift­ly slid­ing $EFTR in­to a pen­ny stock morass, eF­FEC­TOR Ther­a­peu­tics has tapped Dou­glas Warn­er as CMO. Warn­er breaks away from Am­gen af­ter an 18-year run that end­ed as ex­ec­u­tive med­ical di­rec­tor, group prod­uct area lead. Along with tomivosert­ib, he takes charge of eF­FEC­TOR’s ear­ly-stage stud­ies of zo­tat­ifin in sol­id tu­mors and Covid-19. Ken­neth Tru­itt → Ken­neth Tru­itt has signed on as CMO of Aque­s­tive Ther­a­peu­tics, which changed CEOs three months ago as it tries to get in the good graces of the FDA with the seizure drug Liber­vant and its ep­i­neph­rine oral film AQST-109. Tru­itt, whose first day at Aque­s­tive is Sept. 6, spent 16 years at Dai­ichi Sankyo be­fore his ap­point­ments as med­ical chief of Im­mu­sanT in 2018 and Ven­thera a year lat­er. Mean­while, Hu­mani­gen COO and CFO Tim Mor­ris has joined Aque­s­tive’s board of di­rec­tors. Car­o­line Ger­ma → Big Phar­ma vet Car­o­line Ger­ma has been named EVP, glob­al med­i­cine de­vel­op­ment and CMO at Chi­nese an­ti­body biotech Tran­scen­ta. Ger­ma’s CV reads like a who’s who of the in­dus­try: Af­ter six years at Eli Lil­ly, she was clin­i­cal lead for breast can­cer med ner­a­tinib (Ner­l­ynx) dur­ing her four years at Pfiz­er. She then jumped to No­var­tis in 2011, where she rose to se­nior glob­al pro­gram clin­i­cal head for ri­bo­ci­clib (Kisqali) and canakinum­ab. She then left for Bris­tol My­ers in 2018, stay­ing there for a year be­fore join­ing As­traZeneca as VP and head of the ear­ly de­vel­op­ment clin­i­cal group for on­col­o­gy. PJ Ramtin → PJ Ramtin has set­tled in as SVP of busi­ness op­er­a­tions at Spruce Bio­sciences, which is de­vel­op­ing tildac­er­font for en­docrine dis­or­ders such as clas­sic con­gen­i­tal adren­al hy­per­pla­sia. Ramtin joined Spruce in June af­ter three years with Bridge­Bio as VP, com­mer­cial op­er­a­tions and VP, busi­ness op­er­a­tions. Ear­li­er, she was on­col­o­gy busi­ness di­rec­tor at Re­gen­eron and had two sep­a­rate stints at Genen­tech. Vikram Lam­ba → Cal­i­for­nia CAR-T play­er Imm­PACT Bio has had it­self a year with $111 mil­lion in Se­ries B fund­ing , the ad­di­tion of board chair Sheila Gu­jrathi and a grow­ing C-suite that now in­cludes ex-Zosano Phar­ma chief Vikram Lam­ba as CFO and head of busi­ness de­vel­op­ment. The Bay­er vet had been CFO of di­ag­nos­tics com­pa­ny Chro­ma­Code since April 2021. Imm­PACT Bio has al­so ap­point­ed a chief tech­nol­o­gy of­fi­cer (Syl­vain Roy) and COO (Venkat Yepuri) in the last few months. Joy Zhou → Tucked in­to its Q2 re­port, nat­ur­al killer biotech MiNK Ther­a­peu­tics men­tioned that Joy Zhou has been ap­point­ed head of CMC. Zhou is the for­mer head of drug prod­uct de­vel­op­ment, cell ther­a­py at Take­da who re­cent­ly led MS&T (man­u­fac­tur­ing sci­ences & tech­nol­o­gy) at Ru­bius Ther­a­peu­tics; ear­ly in her ca­reer, she was a sci­en­tist at Pfiz­er and J&J. Just be­fore the bot­tom fell out of the sec­tor, MiNK went pub­lic in Oc­to­ber 2021 with a $40 mil­lion IPO. Nicholas Pachu­da → Pe­ter Thiel-backed pep­tide drug de­sign biotech Pep­ti­log­ics has en­list­ed At­ul Desh­pande as chief strat­e­gy of­fi­cer and pro­mot­ed Nicholas Pachu­da to COO. Desh­pande joins the Pitts­burgh-based com­pa­ny from Im­me­di­ate Ther­a­peu­tics, where he served at the helm of the com­pa­ny as CEO. Pri­or to that stint, Desh­pande was chief strat­e­gy of­fi­cer and head of US op­er­a­tions for Har­bour Bio­Med and glob­al op­er­a­tions head for the Dupix­ent fran­chise at Sanofi. Pachu­da joined Pep­ti­log­ics in 2020, start­ing as SVP of port­fo­lio and de­vel­op­ment. Pachu­da hopped aboard Pep­ti­log­ics af­ter a gig at J&J, lead­ing ex­ter­nal in­no­va­tion for the com­pa­ny’s or­tho­pe­dic de­vice fran­chise. Sabine Sydow → Ger­man CD­MO Rentschler Bio­phar­ma, which was slapped with a Form 483 for mul­ti­ple pro­duc­tion is­sues in June, has brought aboard Sabine Sydow as chief of staff and Falk Nuern­berg­er as cor­po­rate gen­er­al coun­sel. Sydow for­mer­ly had a 16-year run with vfa bio, hav­ing served as head. Mean­while, Nuern­berg­er served as gen­er­al coun­sel Eu­rope of Vi­a­tris and has had stints at Medi­Gene, San­doz and Ac­tavis. → Ear­ly can­cer screen­ing and de­tec­tion-fo­cused biotech An­Pac Bio-Med­ical Sci­ence has ush­ered in Yuyang Cui as co-chair­man of the board and co-CEO of the com­pa­ny and Ji­awen Kang as a mem­ber of its board of di­rec­tors. Cui and Kang’s ap­point­ments come as An­Pac has re-shuf­fled some of its board and ex­ec team. An­Pac re­lieved Aidong Chen from his du­ties as co-chair­man and co-CEO and re­moved Sheng Liu from its board. In ad­di­tion, the com­pa­ny has re-des­ig­nat­ed Chris Chang Yu as CEO and chair­man of the board. Joseph Dama­sio → Bio­engi­neer­ing com­pa­ny Biostage has pulled in Joseph Dama­sio as CFO. Dama­sio for­mer­ly served as CGO, VP fi­nance and con­troller at In­hibikase Ther­a­peu­tics, Cue Bio­phar­ma and Pres­sure Bio­sciences. → With the small­pox an­tivi­ral Tem­bexa (brin­cid­o­fovir) await­ing a con­tract sig­na­ture from BAR­DA and talks of po­ten­tial use in the mon­key­pox out­break — af­ter the com­pas­sion­ate-use hub­bub in 2014 that in­volved young Josh Hardy re­ceiv­ing the drug — Chimerix has pegged Christo­pher Jor­dan as VP, reg­u­la­to­ry af­fairs. Jor­dan, an Eli Lil­ly alum, held the role of se­nior glob­al pro­gram reg­u­la­to­ry di­rec­tor at No­var­tis af­ter a string of reg­u­la­to­ry posts at En­do­cyte from 2013-19. → Hous­ton-based TCR-T out­fit Alaunos Ther­a­peu­tics, once known as Boston-based Zio­pharm On­col­o­gy, is bring­ing in Ab­hishek Sri­vas­ta­va as VP, tech­ni­cal op­er­a­tions. A for­mer as­sis­tant pro­fes­sor at the Uni­ver­si­ty of Pitts­burgh School of Med­i­cine, Sri­vas­ta­va comes to Alaunos from Athenex, where he was VP, cell ther­a­py de­vel­op­ment. Mary Mc­Na­ma­ra-Cul­li­nane → Clear­Point Neu­ro has re­cruit­ed Mary Mc­Na­ma­ra-Cul­li­nane as VP of reg­u­la­to­ry af­fairs. Mc­Na­ma­ra-Cul­li­nane joins from Ali­ra Health, where she was SVP of reg­u­la­to­ry af­fairs. Pri­or to that, Mc­Na­ma­ra-Cul­li­nane was prin­ci­pal of MMC reg­u­la­to­ry con­sult­ing at In­trin­sic Ther­a­peu­tics and Echo Ther­a­peu­tics. → Kem­Pharm, which forked over $12.8 mil­lion in cash for Or­p­hazyme and its “pipeline-in-a-prod­uct” in May, has se­lect­ed Nichol Ochsner as VP, in­vestor re­la­tions and cor­po­rate com­mu­ni­ca­tions. Ochsner was pre­vi­ous­ly an in­vestor re­la­tions and com­mu­ni­ca­tions ex­ec with Stat­era Bio­phar­ma and Ther­a­peu­tic­sMD. John Maraganore → Just when you think the Maraganore Me­ter is tak­ing a breather at Peer Re­view, here he comes again: For­mer Al­ny­lam CEO John Maraganore is mak­ing his way to the board of di­rec­tors at ProKid­ney with Nu­va­tion Bio CFO Jen­nifer Fox. The list of board ap­point­ments and ad­vi­so­ry roles for Maraganore is as long as your arm, from chair­ing the board at Hemab Ther­a­peu­tics to help­ing out Over­land Phar­ma­ceu­ti­cals as a strate­gic ad­vi­sor — and be­yond. → For­mer HHS Sec­re­tary Alex Azar has popped up over at 3D Sys­tems as part of the com­pa­ny’s med­ical ad­vi­so­ry board. Azar brings with him a wealth of ex­pe­ri­ence in­clud­ing his time as pres­i­dent of the US di­vi­sion of Eli Lil­ly and as a board mem­ber of BIO. Lead­ing up to his role as HHS sec­re­tary un­der for­mer pres­i­dent Don­ald Trump, Azar for­mer­ly served as gen­er­al coun­sel of HHS start­ing in 2001. Thomas Soloway → Na­tal­ie Holles-led Third Har­mon­ic Bio is shoring up its board of di­rec­tors by ap­point­ing Thomas Soloway. The cur­rent T-knife CEO was Holles’ COO at Au­dentes and he’s al­so on the board at Sat­suma Phar­ma­ceu­ti­cals. → Liv­er dis­ease biotech Al­bireo has elect­ed Habib Dable and Su­san Alesina to the board of di­rec­tors. Dable was pres­i­dent and CEO of Ac­celeron af­ter a 22-year ca­reer with Bay­er, while Alesina is a Mil­li­pore­Sig­ma and Sunovion vet who is VP, na­tion­al busi­ness de­vel­op­ment and al­liances at Boston Chil­dren’s Hos­pi­tal. → MindMed, the com­pa­ny fo­cused on brain health dis­or­ders, has signed on Suzanne Bruhn and Roger Crys­tal to its board of di­rec­tors. Bruhn is pres­i­dent, CEO and di­rec­tor of Tia­ki Ther­a­peu­tics while Crys­tal is the pres­i­dent, CEO and di­rec­tor of Opi­ant Phar­ma­ceu­ti­cals and the lead in­ven­tor of the Nar­can nasal spray. → Carls­bad, CA-based Cu­rate Bio­sciences has tapped Daniel Getts as a new mem­ber of its board of di­rec­tors. Getts is the co-founder and CEO of Myeloid Ther­a­peu­tics and has pre­vi­ous­ly had gigs as VP of re­search at TCR2 Ther­a­peu­tics and co-founder and CSO of Cour Phar­ma­ceu­ti­cals. AUTHORS Max Gelman Senior Editor As public biotechs seek to climb out of the bear market, a popular strategy to raise cash has been through public offerings on the heels of positive data. But one proposed raise Wednesday appeared to take advantage not of a company’s own data, but those from a competitor. Cerevel Therapeutics plans to raise $250 million in a public offering and another $250 million in debt, the biotech announced Wednesday afternoon, even though it did not report any news on its pipeline. However, the move comes days after rival Karuna Therapeutics touted positive Phase III data in schizophrenia, a field where Cerevel is pursuing a similar program. Keep reading Endpoints with a free subscription Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Paul Schloesser Associate Editor Zantac became one of the most well-known drugs on the market after being FDA-approved in 1983 — and now close to four decades later, lawsuits over safety concerns are rattling analysts and investors. Sanofi, GSK and Haleon, GSK’s former consumer healthcare unit, have lost billions of dollars in market cap since Tuesday’s market close,  according to  Bloomberg. While Zantac is no longer on the market, the drop came after a suite of analysts, from Morgan Stanley and other firms, sounded the alarm on the potential impact of ongoing personal injury litigation. Keep reading Endpoints with a free subscription Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Nicole DeFeudis Editor Eli Lilly has found a new chief commercial officer from among the ranks at Bristol Myers Squibb, as it says farewell to its longtime head of human resources Stephen Fry. Fry announced on Thursday his plans to retire after more than 35 years with Lilly. He’ll vacate his seat as SVP of human resources and diversity at the end of the year, and current Loxo CCO Eric Dozier is slated to take his place. As a result, BMS’ Winselow Tucker is joining the team as Loxo CCO at the end of the month. Read More August 11, 2022 10:57 AM EDT Aayushi Pratap News Reporter Evelo Biosciences is on the hunt for a new CEO, with its founding chief Simba Gill switching to the chairman post to free up time for his new gig at Evelo’s incubator, Flagship Pioneering. Gill will trade in his former Flagship title of venture partner with the higher-up role of executive partner, after originally joining in 2015. He’ll serve as CEO of Evelo until his successor is chosen, and at Flagship his priorities will be counseling and supporting the venture firm’s portfolio companies. Keep reading Endpoints with a free subscription Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle LaHucik Associate Editor Menarini and Radius Health are getting a speedy review at the FDA for their oral SERD breast cancer drug months after the field opened up with competitors failing and fleeing. It was a one-two-three punch in March, April and May as Sanofi flunked its first big test for its oral selective estrogen receptor degrader (SERD), Roche also flamed out in a Phase II and G1 Therapeutics ended its program after scoping out the data and potential partners. Keep reading Endpoints with a free subscription Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Beth Snyder Bulik Senior Editor Going back to school is usually a bumpy readjustment from summer freedom for all kids, but especially for kids with chronic health conditions. Horizon Therapeutics is hoping to help smooth the way for some who have the rare disease cystinosis. Cystinosis is a genetic disease that causes the amino acid cystine to build up in different tissues and organs. The “Gear Up” for school campaign is running all week with different online and at-home events and activities for families and children with cystinosis. Each family who signed up receives a care package mailed to their home including an activity coloring book “Michael’s Show-and-Tell.” The book tells Michael’s story about living with cystinosis while offering kids matching, coloring and finding object games along with information. Keep reading Endpoints with a free subscription Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Enanta Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Enanta Pharmaceuticals Rank

  • When was Enanta Pharmaceuticals founded?

    Enanta Pharmaceuticals was founded in 1998.

  • Where is Enanta Pharmaceuticals's headquarters?

    Enanta Pharmaceuticals's headquarters is located at 500 Arsenal Street, Watertown.

  • What is Enanta Pharmaceuticals's latest funding round?

    Enanta Pharmaceuticals's latest funding round is IPO.

  • How much did Enanta Pharmaceuticals raise?

    Enanta Pharmaceuticals raised a total of $106.55M.

  • Who are the investors of Enanta Pharmaceuticals?

    Investors of Enanta Pharmaceuticals include BioVentures Investors, Oxford Bioscience Partners, Advent International, TVM Capital, Thuja Capital Management and 13 more.

  • Who are Enanta Pharmaceuticals's competitors?

    Competitors of Enanta Pharmaceuticals include Carmot Therapeutics, Sequoia Sciences, MerLion Pharmaceuticals, Achaogen, Nuevolution and 12 more.

You May Also Like


Glycopep is engaged in the synthesis and development of unique chemicals and resin products to support drug discovery. Glycopep is providing custom synthesis to academic institutions and pharmaceutical/biotech companies.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Trana Discovery Logo
Trana Discovery

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

Aquapharm Logo

Aquapharm, founded in 2000, is a marine natural products company that uses marine bacteria, a very large untapped reservoir of natural products, and fungi to produce and commercialise functional food compounds and pharmaceuticals. The STF invested as part of a £1.9m funding round to develop Aquapharm's anti-microbial drug discovery business and to conduct pilot-scale manufacture and apply for Food status from the EU and FDA to allow sales into European and US markets.

ProFoldin Protein Folding Services

ProFoldin Protein Folding Services is committed to providing professional services and research tools to academic institutes, biotech and pharmaceutical industries in the area of protein sciences. One of the company's focus area is to help the company's customers to make active proteins from inactive ones, a process called protein folding. ProFoldin aims to provide protein folding columns and reagents and performs customer protein folding services.

AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.